Advice

Following a full submission.

Tigecycline (Tygacil) is accepted for restricted use within NHS Scotland for the treatment of complicated skin and soft-tissue infections.

Tigecycline is associated with clinical cure rates in patients with complicated skin and skin structure infections non-inferior to those with a combination of a glycopeptide and a monocyclic beta-lactam antibiotic.

It is restricted to use as a 2nd or 3rd line agent under the advice of local microbiologists or specialists in infectious diseases.

Download detailed advice46KB (PDF)

Download

Medicine details

Medicine name:
tigecycline 50mg vial of powder tigecycline for intravenous infusion (Tygacil)
SMC ID:
276/06
Indication:
Complicated skin and soft-tissue infections
Pharmaceutical company
Wyeth Pharmaceuticals
BNF chapter
Infections
Submission type
Full
Status
Restricted
Date advice published
10 July 2006